Zhitong Financial APP learned that$Pfizer Inc (PFE.US) $It said on Tuesday that it would suspend trials of its oral drug Paxlovid against novel coronavirus in patients at standard risk. A previous study showed that the drug had no effect on people with mild illness.

It is reported that quasi-risk groups usually refer to people who are not at risk of serious illness and who can recover on their own without drugs. The data show that the relative risk of the standard risk group has been reduced by 51%, which Pfizer Inc said is not statistically significant.

At present, Paxlovid has been authorized for emergency use in high-risk groups, which can effectively reduce hospitalization and mortality. According to the U.S. Department of Health and Human Services, more than 1.2 million courses of Paxlovid have been used in the United States. Pfizer Inc said the plan would submit an application to the US Food and Drug Administration (FDA) to include the new data to seek full approval for the drug to be used in high-risk groups.

Data from a study conducted in Israel earlier this month showed that Paxlovid reduced COVID-19 's hospitalization and mortality rates among vaccinated and unvaccinated patients aged 65 and older, but did not find that the drug could prevent serious diseases in young people.